Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frits van Rhee

Showing results (221-230 of 274) with videos related to

Pageof 28
Sort By:
Blood Cancer Journal|November 6, 2024
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stagesYan Cheng, Fumou Sun, Daisy V Alapat, et al.
The Journal of Clinical Investigation|July 26, 2022
CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiationDongzheng Gai, Jin-Ran Chen, James P Stewart, et al.
Blood Cancer Journal|June 20, 2020
Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patternsCarolina Schinke, Eileen M Boyle, Cody Ashby, et al.
Haematologica|May 28, 2017
The level of deletion 17p and bi-allelic inactivation of <i>TP53</i> has a significant impact on clinical outcome in multiple myelomaSharmilan Thanendrarajan, Erming Tian, Pingping Qu, et al.
Current Research in Translational Medicine|April 24, 2021
PHF19 inhibition as a therapeutic target in multiple myelomaCarolina D Schinke, Jordan T Bird, Pingping Qu, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|November 22, 2014
Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patientsSusann Szmania, Natalia Lapteva, Tarun Garg, et al.
British Journal of Haematology|August 31, 2006
Long-term outcome results of the first tandem autotransplant trial for multiple myelomaBart Barlogie, Guido J Tricot, Frits van Rhee, et al.
Blood Cancer Journal|April 23, 2025
Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myelomaMeera Mohan, Aniko Szabo, Heloise Cheruvalath, et al.
Blood|April 23, 2017
Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myelomaLeo Rasche, Edgardo Angtuaco, James E McDonald, et al.
Journal of Hematology & Oncology|June 29, 2023
A gene signature can predict risk of MGUS progressing to multiple myelomaFumou Sun, Yan Cheng, Jun Ying, et al.
Pageof 28

Showing results (221-230 of 274) with videos related to

Sort By:
Pageof 28
Blood Cancer Journal|November 6, 2024
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stagesYan Cheng, Fumou Sun, Daisy V Alapat, et al.
The Journal of Clinical Investigation|July 26, 2022
CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiationDongzheng Gai, Jin-Ran Chen, James P Stewart, et al.
Blood Cancer Journal|June 20, 2020
Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patternsCarolina Schinke, Eileen M Boyle, Cody Ashby, et al.
Haematologica|May 28, 2017
The level of deletion 17p and bi-allelic inactivation of <i>TP53</i> has a significant impact on clinical outcome in multiple myelomaSharmilan Thanendrarajan, Erming Tian, Pingping Qu, et al.
Current Research in Translational Medicine|April 24, 2021
PHF19 inhibition as a therapeutic target in multiple myelomaCarolina D Schinke, Jordan T Bird, Pingping Qu, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|November 22, 2014
Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patientsSusann Szmania, Natalia Lapteva, Tarun Garg, et al.
British Journal of Haematology|August 31, 2006
Long-term outcome results of the first tandem autotransplant trial for multiple myelomaBart Barlogie, Guido J Tricot, Frits van Rhee, et al.
Blood Cancer Journal|April 23, 2025
Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myelomaMeera Mohan, Aniko Szabo, Heloise Cheruvalath, et al.
Blood|April 23, 2017
Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myelomaLeo Rasche, Edgardo Angtuaco, James E McDonald, et al.
Journal of Hematology & Oncology|June 29, 2023
A gene signature can predict risk of MGUS progressing to multiple myelomaFumou Sun, Yan Cheng, Jun Ying, et al.
Pageof 28